ID   RHG07_HUMAN             Reviewed;        1528 AA.
AC   Q96QB1; B4DR10; B8PTI0; E9PDZ8; E9PF76; E9PGY9; O14868; O43199; Q7Z5R8;
AC   Q86UC6; Q9C0E0; Q9H7A2;
DT   08-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 4.
DT   28-JUN-2023, entry version 191.
DE   RecName: Full=Rho GTPase-activating protein 7;
DE   AltName: Full=Deleted in liver cancer 1 protein;
DE            Short=DLC-1;
DE   AltName: Full=HP protein;
DE   AltName: Full=Rho-type GTPase-activating protein 7;
DE   AltName: Full=START domain-containing protein 12;
DE            Short=StARD12;
DE   AltName: Full=StAR-related lipid transfer protein 12;
GN   Name=DLC1; Synonyms=ARHGAP7, KIAA1723, STARD12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SER-712; VAL-1199 AND
RP   CYS-1209.
RX   PubMed=9605766;
RA   Yuan B.Z., Miller M.J., Keck C.L., Zimonjic D.B., Thorgeirsson S.S.,
RA   Popescu N.C.;
RT   "Cloning, characterization, and chromosomal localization of a gene
RT   frequently deleted in human liver cancer (DLC-1) homologous to rat
RT   RhoGAP.";
RL   Cancer Res. 58:2196-2199(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-791.
RC   TISSUE=Lung;
RA   Wei M.-H., Pack S., Ivanov S., Lerman M.I.;
RT   "Cloning and molecular characterization of the human ortholog of the rat
RT   dual regulator p122RhoGAP.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT MET-791.
RA   Jeong S.-J., Dimtchev A., Lerman M., Dritschilo A., Jung M.;
RT   "Identification of HP/DLC1 exon and introns.";
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS HIS-254;
RP   ASP-255 AND ILE-260 AND MET-791.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS
RP   HIS-254; ASP-255; ILE-260 AND MET-791.
RC   TISSUE=Smooth muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5), AND VARIANT
RP   ASP-255.
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-50 (ISOFORM 6), AND ALTERNATIVE PROMOTER
RP   USAGE.
RC   TISSUE=Liver;
RX   PubMed=21217778; DOI=10.1038/onc.2010.576;
RA   Low J.S., Tao Q., Ng K.M., Goh H.K., Shu X.S., Woo W.L., Ambinder R.F.,
RA   Srivastava G., Shamay M., Chan A.T., Popescu N.C., Hsieh W.S.;
RT   "A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor
RT   growth and is frequently silenced in multiple common tumors.";
RL   Oncogene 30:1923-1935(2011).
RN   [9]
RP   INTERACTION WITH TNS4, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-877 AND
RP   TYR-879.
RX   PubMed=17190795; DOI=10.1083/jcb.200608015;
RA   Liao Y.C., Si L., deVere White R.W., Lo S.H.;
RT   "The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of
RT   cten regulates focal adhesion localization and growth suppression activity
RT   of DLC-1.";
RL   J. Cell Biol. 176:43-49(2007).
RN   [10]
RP   FUNCTION, DOMAIN SAM, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-879.
RX   PubMed=18786931; DOI=10.1074/jbc.m800617200;
RA   Kim T.Y., Healy K.D., Der C.J., Sciaky N., Bang Y.J., Juliano R.L.;
RT   "Effects of structure of Rho GTPase-activating protein DLC-1 on cell
RT   morphology and migration.";
RL   J. Biol. Chem. 283:32762-32770(2008).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND FOCAL ADHESION TARGETING.
RX   PubMed=19170769; DOI=10.1111/j.1365-2443.2008.01265.x;
RA   Kawai K., Iwamae Y., Yamaga M., Kiyota M., Ishii H., Hirata H., Homma Y.,
RA   Yagisawa H.;
RT   "Focal adhesion-localization of START-GAP1/DLC1 is essential for cell
RT   motility and morphology.";
RL   Genes Cells 14:227-241(2009).
RN   [12]
RP   INTERACTION WITH TNS1.
RX   PubMed=19826001; DOI=10.1074/jbc.m109.059592;
RA   Hall E.H., Daugherty A.E., Choi C.K., Horwitz A.F., Brautigan D.L.;
RT   "Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to
RT   control cell polarization, migration, and invasion.";
RL   J. Biol. Chem. 284:34713-34722(2009).
RN   [13]
RP   FUNCTION, AND LIPID-BINDING REGION.
RX   PubMed=19710422; DOI=10.1091/mbc.e09-03-0247;
RA   Erlmann P., Schmid S., Horenkamp F.A., Geyer M., Pomorski T.G.,
RA   Olayioye M.A.;
RT   "DLC1 activation requires lipid interaction through a polybasic region
RT   preceding the RhoGAP domain.";
RL   Mol. Biol. Cell 20:4400-4411(2009).
RN   [14]
RP   INTERACTION WITH TNS1.
RX   PubMed=20798394; DOI=10.1074/mcp.m110.003665;
RA   Hall E.H., Balsbaugh J.L., Rose K.L., Shabanowitz J., Hunt D.F.,
RA   Brautigan D.L.;
RT   "Comprehensive analysis of phosphorylation sites in Tensin1 reveals
RT   regulation by p38MAPK.";
RL   Mol. Cell. Proteomics 9:2853-2863(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-523; SER-526 AND SER-757, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   INTERACTION WITH TNS1.
RX   PubMed=26427649; DOI=10.1016/j.bbamcr.2015.09.028;
RA   Shih Y.P., Sun P., Wang A., Lo S.H.;
RT   "Tensin1 positively regulates RhoA activity through its interaction with
RT   DLC1.";
RL   Biochim. Biophys. Acta 1853:3258-3265(2015).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH TNS3 AND PTEN.
RX   PubMed=26166433; DOI=10.1038/ncomms8721;
RA   Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.;
RT   "A phosphorylation switch controls the spatiotemporal activation of Rho
RT   GTPases in directional cell migration.";
RL   Nat. Commun. 6:7721-7721(2015).
RN   [19]
RP   STRUCTURE BY NMR OF 438-518.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SAM-domain of rho-GTPase-activating protein 7.";
RL   Submitted (APR-2007) to the PDB data bank.
RN   [20]
RP   STRUCTURE BY NMR OF 454-513.
RX   PubMed=19317456; DOI=10.1021/bi9000936;
RA   Yang S., Noble C.G., Yang D.;
RT   "Characterization of DLC1-SAM equilibrium unfolding at the amino acid
RT   residue level.";
RL   Biochemistry 48:4040-4049(2009).
RN   [21]
RP   STRUCTURE BY NMR OF 451-513, MUTAGENESIS OF PHE-475; LEU-476 AND ARG-1114,
RP   INTERACTION WITH EF1A1, AND SUBCELLULAR LOCATION.
RX   PubMed=19158340; DOI=10.1242/jcs.027482;
RA   Zhong D., Zhang J., Yang S., Soh U.J., Buschdorf J.P., Zhou Y.T., Yang D.,
RA   Low B.C.;
RT   "The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell
RT   migration.";
RL   J. Cell Sci. 122:414-424(2009).
RN   [22]
RP   VARIANTS SER-712; MET-791; ALA-959; GLN-998; ALA-1025; VAL-1199 AND
RP   CYS-1209.
RX   PubMed=10649492;
RX   DOI=10.1002/(sici)1098-1004(200002)15:2<156::aid-humu4>3.0.co;2-4;
RA   Wilson P.J., McGlinn E., Marsh A., Evans T., Arnold J., Wright K.,
RA   Biden K., Young J., Wainwright B., Wicking C., Chenevix-Trench G.;
RT   "Sequence variants of DLC1 in colorectal and ovarian tumours.";
RL   Hum. Mutat. 15:156-165(2000).
CC   -!- FUNCTION: Functions as a GTPase-activating protein for the small
CC       GTPases RHOA, RHOB, RHOC and CDC42, terminating their downstream
CC       signaling. This induces morphological changes and detachment through
CC       cytoskeletal reorganization, playing a critical role in biological
CC       processes such as cell migration and proliferation. Also functions in
CC       vivo as an activator of the phospholipase PLCD1. Active DLC1 increases
CC       cell migration velocity but reduces directionality. Required for growth
CC       factor-induced epithelial cell migration; in resting cells, interacts
CC       with TNS3 while PTEN interacts with the p85 regulatory subunit of the
CC       PI3K kinase complex but growth factor stimulation induces
CC       phosphorylation of TNS3 and PTEN, causing them to change their binding
CC       preference so that PTEN interacts with DLC1 and TNS3 interacts with p85
CC       (PubMed:26166433). The PTEN-DLC1 complex translocates to the posterior
CC       of migrating cells to activate RHOA while the TNS3-p85 complex
CC       translocates to the leading edge of migrating cells to promote RAC1
CC       activation (PubMed:26166433). {ECO:0000269|PubMed:18786931,
CC       ECO:0000269|PubMed:19170769, ECO:0000269|PubMed:19710422,
CC       ECO:0000269|PubMed:26166433}.
CC   -!- SUBUNIT: Interacts with EF1A1, facilitates EF1A1 distribution to the
CC       membrane periphery and ruffles upon growth factor stimulation and
CC       suppresses cell migration (PubMed:19158340). Interacts with tensin TNS1
CC       (via N-terminus); the interaction is decreased by phosphorylation of
CC       TNS1 (PubMed:19826001, PubMed:20798394, PubMed:26427649). Interacts
CC       with TNS3 and PTEN; in resting cells, interacts with TNS3 (via C2
CC       tensin-type domain) but, following growth factor stimulation, TNS3 and
CC       PTEN are phosphorylated which leads to weakened interaction with TNS3
CC       and enhanced interaction with PTEN (PubMed:26166433). Interacts (via C-
CC       terminus) with tensin TNS4 (via SH2 domain); the interaction is
CC       independent of tyrosine phosphorylation of DLC1 (PubMed:17190795).
CC       {ECO:0000269|PubMed:17190795, ECO:0000269|PubMed:19158340,
CC       ECO:0000269|PubMed:19826001, ECO:0000269|PubMed:20798394,
CC       ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26427649}.
CC   -!- INTERACTION:
CC       Q96QB1; P20936: RASA1; NbExp=7; IntAct=EBI-2608428, EBI-1026476;
CC       Q96QB1; Q923Q2: Stard13; Xeno; NbExp=2; IntAct=EBI-2608428, EBI-8393503;
CC       Q96QB1-1; Q04205: TNS; Xeno; NbExp=7; IntAct=EBI-15638708, EBI-2607590;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:17190795}. Membrane; Peripheral membrane protein.
CC       Note=Colocalizes with EF1A1 at actin-rich regions in the cell
CC       periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC       Name=2;
CC         IsoId=Q96QB1-2; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q96QB1-1; Sequence=VSP_037871, VSP_037872;
CC       Name=3;
CC         IsoId=Q96QB1-3; Sequence=VSP_037873, VSP_037874;
CC       Name=4;
CC         IsoId=Q96QB1-4; Sequence=VSP_037871, VSP_044651;
CC       Name=5;
CC         IsoId=Q96QB1-5; Sequence=VSP_046331, VSP_046332;
CC       Name=6; Synonyms=i-4;
CC         IsoId=Q96QB1-6; Sequence=VSP_053836, VSP_053837;
CC   -!- TISSUE SPECIFICITY: Highest level of expression in the spleen, with
CC       rather lower levels in prostate, testis, ovary, small intestine and
CC       colon, but none in the thymus.
CC   -!- DOMAIN: The SAM domain mediates interaction with EF1A1, and functions
CC       as an autoinhibitory regulator of RhoGAP Activity.
CC       {ECO:0000269|PubMed:18786931}.
CC   -!- DOMAIN: The polybasic cluster is required for activation and mediates
CC       binding to phosphatidylinositol-4,5-bisphosphate (PI(4,5)P(2))
CC       containing membranes. {ECO:0000269|PubMed:18786931}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative promoter usage.
CC       ubiquitously expressed, significantly down-regulated in multiple
CC       carcinoma cell lines. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB81637.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB21814.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40328/DLC1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF035119; AAB87700.1; -; mRNA.
DR   EMBL; AF026219; AAB81637.1; ALT_INIT; mRNA.
DR   EMBL; AF408781; AAK97501.1; -; Genomic_DNA.
DR   EMBL; AF408768; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408769; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408770; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408771; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408772; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408773; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408774; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408775; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408776; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408777; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408778; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408779; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AF408780; AAK97501.1; JOINED; Genomic_DNA.
DR   EMBL; AB051510; BAB21814.1; ALT_INIT; mRNA.
DR   EMBL; AK024774; BAB14996.1; -; mRNA.
DR   EMBL; AK299049; BAG61122.1; -; mRNA.
DR   EMBL; AC015641; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC019270; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022844; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC106845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC049842; AAH49842.1; -; mRNA.
DR   EMBL; BC054511; AAH54511.1; -; mRNA.
DR   EMBL; EU159199; ABX83661.1; -; mRNA.
DR   EMBL; EU159200; ABX83662.1; -; mRNA.
DR   CCDS; CCDS55201.1; -. [Q96QB1-4]
DR   CCDS; CCDS5989.1; -. [Q96QB1-2]
DR   CCDS; CCDS5990.1; -. [Q96QB1-1]
DR   CCDS; CCDS5991.2; -. [Q96QB1-5]
DR   CCDS; CCDS83253.1; -. [Q96QB1-6]
DR   RefSeq; NP_001157743.1; NM_001164271.1. [Q96QB1-4]
DR   RefSeq; NP_001303597.1; NM_001316668.1. [Q96QB1-6]
DR   RefSeq; NP_001335010.1; NM_001348081.1. [Q96QB1-2]
DR   RefSeq; NP_001335011.1; NM_001348082.1. [Q96QB1-4]
DR   RefSeq; NP_001335012.1; NM_001348083.1. [Q96QB1-4]
DR   RefSeq; NP_001335013.1; NM_001348084.1. [Q96QB1-4]
DR   RefSeq; NP_006085.2; NM_006094.4. [Q96QB1-1]
DR   RefSeq; NP_079043.3; NM_024767.3. [Q96QB1-5]
DR   RefSeq; NP_872584.2; NM_182643.2. [Q96QB1-2]
DR   RefSeq; XP_005273431.1; XM_005273374.1.
DR   PDB; 2DKY; NMR; -; A=451-515.
DR   PDB; 2GYT; NMR; -; A=451-513.
DR   PDB; 2KAP; NMR; -; A=454-513.
DR   PDB; 2LOZ; NMR; -; B=811-824.
DR   PDB; 3KUQ; X-ray; 2.30 A; A=1074-1283.
DR   PDB; 5FZT; X-ray; 2.10 A; B=904-926.
DR   PDBsum; 2DKY; -.
DR   PDBsum; 2GYT; -.
DR   PDBsum; 2KAP; -.
DR   PDBsum; 2LOZ; -.
DR   PDBsum; 3KUQ; -.
DR   PDBsum; 5FZT; -.
DR   AlphaFoldDB; Q96QB1; -.
DR   BMRB; Q96QB1; -.
DR   SMR; Q96QB1; -.
DR   BioGRID; 115667; 57.
DR   CORUM; Q96QB1; -.
DR   DIP; DIP-56928N; -.
DR   IntAct; Q96QB1; 40.
DR   MINT; Q96QB1; -.
DR   STRING; 9606.ENSP00000276297; -.
DR   GlyGen; Q96QB1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96QB1; -.
DR   PhosphoSitePlus; Q96QB1; -.
DR   BioMuta; DLC1; -.
DR   DMDM; 313104315; -.
DR   EPD; Q96QB1; -.
DR   jPOST; Q96QB1; -.
DR   MassIVE; Q96QB1; -.
DR   MaxQB; Q96QB1; -.
DR   PaxDb; Q96QB1; -.
DR   PeptideAtlas; Q96QB1; -.
DR   ProteomicsDB; 19782; -.
DR   ProteomicsDB; 20045; -.
DR   ProteomicsDB; 20421; -.
DR   ProteomicsDB; 77848; -. [Q96QB1-2]
DR   ProteomicsDB; 77849; -. [Q96QB1-1]
DR   ProteomicsDB; 77850; -. [Q96QB1-3]
DR   Antibodypedia; 22182; 263 antibodies from 36 providers.
DR   CPTC; Q96QB1; 3 antibodies.
DR   DNASU; 10395; -.
DR   Ensembl; ENST00000276297.9; ENSP00000276297.4; ENSG00000164741.15. [Q96QB1-2]
DR   Ensembl; ENST00000316609.9; ENSP00000321034.5; ENSG00000164741.15. [Q96QB1-3]
DR   Ensembl; ENST00000358919.6; ENSP00000351797.2; ENSG00000164741.15. [Q96QB1-1]
DR   Ensembl; ENST00000511869.1; ENSP00000425878.1; ENSG00000164741.15. [Q96QB1-5]
DR   Ensembl; ENST00000512044.6; ENSP00000422595.2; ENSG00000164741.15. [Q96QB1-6]
DR   Ensembl; ENST00000520226.5; ENSP00000428028.1; ENSG00000164741.15. [Q96QB1-4]
DR   GeneID; 10395; -.
DR   KEGG; hsa:10395; -.
DR   MANE-Select; ENST00000276297.9; ENSP00000276297.4; NM_182643.3; NP_872584.2.
DR   UCSC; uc003wwk.2; human. [Q96QB1-2]
DR   AGR; HGNC:2897; -.
DR   CTD; 10395; -.
DR   DisGeNET; 10395; -.
DR   GeneCards; DLC1; -.
DR   HGNC; HGNC:2897; DLC1.
DR   HPA; ENSG00000164741; Low tissue specificity.
DR   MalaCards; DLC1; -.
DR   MIM; 604258; gene.
DR   neXtProt; NX_Q96QB1; -.
DR   OpenTargets; ENSG00000164741; -.
DR   PharmGKB; PA27351; -.
DR   VEuPathDB; HostDB:ENSG00000164741; -.
DR   eggNOG; KOG2200; Eukaryota.
DR   GeneTree; ENSGT00950000183061; -.
DR   HOGENOM; CLU_004367_1_0_1; -.
DR   InParanoid; Q96QB1; -.
DR   OMA; AMSHESM; -.
DR   OrthoDB; 2883046at2759; -.
DR   PhylomeDB; Q96QB1; -.
DR   TreeFam; TF314044; -.
DR   PathwayCommons; Q96QB1; -.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   SignaLink; Q96QB1; -.
DR   SIGNOR; Q96QB1; -.
DR   BioGRID-ORCS; 10395; 12 hits in 1151 CRISPR screens.
DR   ChiTaRS; DLC1; human.
DR   EvolutionaryTrace; Q96QB1; -.
DR   GeneWiki; DLC1; -.
DR   GenomeRNAi; 10395; -.
DR   Pharos; Q96QB1; Tbio.
DR   PRO; PR:Q96QB1; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q96QB1; protein.
DR   Bgee; ENSG00000164741; Expressed in adrenal tissue and 180 other tissues.
DR   ExpressionAtlas; Q96QB1; baseline and differential.
DR   Genevisible; Q96QB1; HS.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:InterPro.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0048041; P:focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; ISS:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0021575; P:hindbrain morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; ISS:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProtKB.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IBA:GO_Central.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   CDD; cd04375; RhoGAP_DLC1; 1.
DR   CDD; cd09591; SAM_DLC1; 1.
DR   CDD; cd08908; START_STARD12-like; 1.
DR   Gene3D; 1.10.287.2070; -; 1.
DR   Gene3D; 3.30.530.20; -; 1.
DR   Gene3D; 1.10.555.10; Rho GTPase activation protein; 1.
DR   IDEAL; IID00677; -.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR023393; START-like_dom_sf.
DR   InterPro; IPR002913; START_lipid-bd_dom.
DR   PANTHER; PTHR12659:SF2; RHO GTPASE-ACTIVATING PROTEIN 7; 1.
DR   PANTHER; PTHR12659; RHO-TYPE GTPASE ACTIVATING PROTEIN; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   Pfam; PF01852; START; 1.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00234; START; 1.
DR   SUPFAM; SSF55961; Bet v1-like; 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   SUPFAM; SSF47769; SAM/Pointed domain; 1.
DR   PROSITE; PS50238; RHOGAP; 1.
DR   PROSITE; PS50848; START; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Cell junction; Cytoplasm; GTPase activation; Membrane; Phosphoprotein;
KW   Reference proteome; Tumor suppressor.
FT   CHAIN           1..1528
FT                   /note="Rho GTPase-activating protein 7"
FT                   /id="PRO_0000056707"
FT   DOMAIN          448..515
FT                   /note="SAM"
FT   DOMAIN          1078..1284
FT                   /note="Rho-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00172"
FT   DOMAIN          1314..1521
FT                   /note="START"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00197"
FT   REGION          72..94
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          288..310
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          372..436
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          558..617
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          710..884
FT                   /note="Focal adhesion-targeting (FAT)"
FT   REGION          732..764
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          829..876
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          928..990
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1051..1073
FT                   /note="Polybasic cluster (PBR)"
FT   COMPBIAS        76..94
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        398..436
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        586..617
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         566
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63744"
FT   MOD_RES         757
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..437
FT                   /note="Missing (in isoform 1 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:9605766, ECO:0000303|Ref.2"
FT                   /id="VSP_037871"
FT   VAR_SEQ         1..45
FT                   /note="MSVAIRKRSWEEHVTHWMGQPFNSDDRNTACHHGLVADSLQASME -> MGD
FT                   PKAHVMARPLRAPLRRSFSDHIRDSTARALDVIWKNTRDRRL (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:21217778"
FT                   /id="VSP_053836"
FT   VAR_SEQ         46..448
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:21217778"
FT                   /id="VSP_053837"
FT   VAR_SEQ         438..511
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044651"
FT   VAR_SEQ         438..450
FT                   /note="TAIQGISEKEKAE -> MCRKKPDTMILTQ (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:9605766, ECO:0000303|Ref.2"
FT                   /id="VSP_037872"
FT   VAR_SEQ         450..498
FT                   /note="EIEAKEACDWLRATGFPQYAQLYEDFLFPIDISLVKREHDFLDRDAIEA ->
FT                   AVKSVKLEVDEDKSTKGSNFSNSEVAIGLSPYTFPQKRLFHVAGEENIT (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037873"
FT   VAR_SEQ         450..463
FT                   /note="EIEAKEACDWLRAT -> GKLTFWFCFLANLF (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_046331"
FT   VAR_SEQ         464..1528
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_046332"
FT   VAR_SEQ         499..1528
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037874"
FT   VARIANT         27
FT                   /note="R -> C (in dbSNP:rs34575560)"
FT                   /id="VAR_059293"
FT   VARIANT         81
FT                   /note="L -> V (in dbSNP:rs3816748)"
FT                   /id="VAR_059294"
FT   VARIANT         254
FT                   /note="Q -> H (in dbSNP:rs11203495)"
FT                   /evidence="ECO:0000269|PubMed:11214970,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_059295"
FT   VARIANT         255
FT                   /note="N -> D (in dbSNP:rs11203494)"
FT                   /evidence="ECO:0000269|PubMed:11214970,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_059296"
FT   VARIANT         260
FT                   /note="T -> I (in dbSNP:rs3816747)"
FT                   /evidence="ECO:0000269|PubMed:11214970,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_059297"
FT   VARIANT         320
FT                   /note="Q -> H (in dbSNP:rs34591797)"
FT                   /id="VAR_059298"
FT   VARIANT         712
FT                   /note="N -> S (in dbSNP:rs1044092)"
FT                   /evidence="ECO:0000269|PubMed:10649492,
FT                   ECO:0000269|PubMed:9605766"
FT                   /id="VAR_014229"
FT   VARIANT         791
FT                   /note="V -> M (in dbSNP:rs532841)"
FT                   /evidence="ECO:0000269|PubMed:10649492,
FT                   ECO:0000269|PubMed:11214970, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|Ref.2, ECO:0000269|Ref.3"
FT                   /id="VAR_014230"
FT   VARIANT         959
FT                   /note="T -> A (in dbSNP:rs121908500)"
FT                   /evidence="ECO:0000269|PubMed:10649492"
FT                   /id="VAR_014231"
FT   VARIANT         998
FT                   /note="H -> Q (in dbSNP:rs149295187)"
FT                   /evidence="ECO:0000269|PubMed:10649492"
FT                   /id="VAR_014232"
FT   VARIANT         1025
FT                   /note="V -> A"
FT                   /evidence="ECO:0000269|PubMed:10649492"
FT                   /id="VAR_014233"
FT   VARIANT         1199
FT                   /note="E -> V (in dbSNP:rs1044093)"
FT                   /evidence="ECO:0000269|PubMed:10649492,
FT                   ECO:0000269|PubMed:9605766"
FT                   /id="VAR_014234"
FT   VARIANT         1209
FT                   /note="S -> C (in dbSNP:rs1044094)"
FT                   /evidence="ECO:0000269|PubMed:10649492,
FT                   ECO:0000269|PubMed:9605766"
FT                   /id="VAR_014235"
FT   MUTAGEN         475
FT                   /note="F->G: Abolishes interaction with EF1A1."
FT                   /evidence="ECO:0000269|PubMed:19158340"
FT   MUTAGEN         476
FT                   /note="L->G: Abolishes interaction with EF1A1."
FT                   /evidence="ECO:0000269|PubMed:19158340"
FT   MUTAGEN         877
FT                   /note="S->A: Abolishes interaction with TNS4 and results in
FT                   diffuse cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:17190795"
FT   MUTAGEN         879
FT                   /note="Y->F: Unable to displace endogenous DLC1 from focal
FT                   adhesions. Abolishes interaction with TNS4 and results in
FT                   diffuse cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:17190795,
FT                   ECO:0000269|PubMed:18786931"
FT   MUTAGEN         1114
FT                   /note="R->E: No catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:19158340"
FT   CONFLICT        43
FT                   /note="S -> C (in Ref. 5; BAB14996)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        130
FT                   /note="T -> I (in Ref. 5; BAB14996)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        571
FT                   /note="H -> L (in Ref. 4; BAB21814)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1114
FT                   /note="R -> K (in Ref. 1; AAB87700)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1364
FT                   /note="P -> R (in Ref. 1; AAB87700)"
FT                   /evidence="ECO:0000305"
FT   HELIX           449..463
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   HELIX           468..473
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   TURN            474..476
FT                   /evidence="ECO:0007829|PDB:2KAP"
FT   HELIX           481..487
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   TURN            488..490
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   HELIX           493..509
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   TURN            510..514
FT                   /evidence="ECO:0007829|PDB:2DKY"
FT   HELIX           906..920
FT                   /evidence="ECO:0007829|PDB:5FZT"
FT   HELIX           1080..1087
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   STRAND          1088..1091
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1093..1105
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   TURN            1110..1114
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1119..1129
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   STRAND          1131..1134
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1143..1156
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   STRAND          1157..1159
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1166..1176
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1179..1181
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1182..1191
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1195..1213
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1215..1218
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1222..1234
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   HELIX           1260..1278
FT                   /evidence="ECO:0007829|PDB:3KUQ"
FT   CONFLICT        Q96QB1-6:49..50
FT                   /note="EA -> KP (in Ref. 8; ABX83661/ABX83662)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1528 AA;  170591 MW;  5D20F29CC606302E CRC64;
     MSVAIRKRSW EEHVTHWMGQ PFNSDDRNTA CHHGLVADSL QASMEKDATL NVDRKEKCVS
     LPDCCHGSEL RDFPGRPMGH LSKDVDENDS HEGEDQFLSL EASTETLVHV SDEDNNADLC
     LTDDKQVLNT QGQKTSGQHM IQGAGSLEKA LPIIQSNQVS SNSWGIAGET ELALVKESGE
     RKVTDSISKS LELCNEISLS EIKDAPKVNA VDTLNVKDIA PEKQLLNSAV IAQQRRKPDP
     PKDENERSTC NVVQNEFLDT PCTNRGLPLL KTDFGSCLLQ PPSCPNGMSA ENGLEKSGFS
     QHQNKSPPKV KAEDGMQCLQ LKETLATQEP TDNQVRLRKR KEIREDRDRA RLDSMVLLIM
     KLDQLDQDIE NALSTSSSPS GTPTNLRRHV PDLESGSESG ADTISVNQTR VNLSSDTEST
     DLPSSTPVAN SGTKPKTTAI QGISEKEKAE IEAKEACDWL RATGFPQYAQ LYEDFLFPID
     ISLVKREHDF LDRDAIEALC RRLNTLNKCA VMKLEISPHR KRSDDSDEDE PCAISGKWTF
     QRDSKRWSRL EEFDVFSPKQ DLVPGSPDDS HPKDGPSPGG TLMDLSERQE VSSVRSLSST
     GSLPSHAPPS EDAATPRTNS VISVCSSSNL AGNDDSFGSL PSPKELSSFS FSMKGHEKTA
     KSKTRSLLKR MESLKLKSSH HSKHKAPSKL GLIISGPILQ EGMDEEKLKQ LNCVEISALN
     GNRINVPMVR KRSVSNSTQT SSSSSQSETS SAVSTPSPVT RTRSLSACNK RVGMYLEGFD
     PFNQSTFNNV VEQNFKNRES YPEDTVFYIP EDHKPGTFPK ALTNGSFSPS GNNGSVNWRT
     GSFHGPGHIS LRRENSSDSP KELKRRNSSS SMSSRLSIYD NVPGSILYSS SGDLADLENE
     DIFPELDDIL YHVKGMQRIV NQWSEKFSDE GDSDSALDSV SPCPSSPKQI HLDVDNDRTT
     PSDLDSTGNS LNEPEEPSEI PERRDSGVGA SLTRSNRHRL RWHSFQSSHR PSLNSVSLQI
     NCQSVAQMNL LQKYSLLKLT ALLEKYTPSN KHGFSWAVPK FMKRIKVPDY KDRSVFGVPL
     TVNVQRTGQP LPQSIQQAMR YLRNHCLDQV GLFRKSGVKS RIQALRQMNE GAIDCVNYEG
     QSAYDVADML KQYFRDLPEP LMTNKLSETF LQIYQYVPKD QRLQAIKAAI MLLPDENREV
     LQTLLYFLSD VTAAVKENQM TPTNLAVCLA PSLFHLNTLK RENSSPRVMQ RKQSLGKPDQ
     KDLNENLAAT QGLAHMIAEC KKLFQVPEEM SRCRNSYTEQ ELKPLTLEAL GHLGNDDSAD
     YQHFLQDCVD GLFKEVKEKF KGWVSYSTSE QAELSYKKVS EGPPLRLWRS VIEVPAVPEE
     ILKRLLKEQH LWDVDLLDSK VIEILDSQTE IYQYVQNSMA PHPARDYVVL RTWRTNLPKG
     ACALLLTSVD HDRAPVVGVR VNVLLSRYLI EPCGPGKSKL TYMCRVDLRG HMPEWYTKSF
     GHLCAAEVVK IRDSFSNQNT ETKDTKSR
//
